Insider Cluster (3 insiders) ·Filed Mar 26, 2026

NUVL

Nuvalent, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago
Insider cluster: 3 insiders, $0.7M total
Actionable Insight • Neutral

The sales are small relative to company size and likely represent routine post-exercise diversification; monitor for recurrence or larger-scale selling. No immediate red flags, but watch for absence of insider buying ahead of next earnings or catalyst.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
NUVL ▲ +25.93% at T+60d
NEUTRAL call ✓ call won +25.93% · α vs SPY +11.98% · entry $98.06 → $123.49
Entry anchored
Mar 25, 03:59 PM ET
via exchange tick
T+1d
-1.43%
call -1.43% · α +0.25%
$96.66
settled 6mo ago
T+5d
+7.52%
call +7.52% · α +5.88%
$105.43
settled 6mo ago
T+20d
+6.57%
call +6.57% · α -4.10%
$104.50
settled 5mo ago
T+60d
+25.93%
call +25.93% · α +11.98%
$123.49
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Three Nuvalent executives, including the CFO and Chief Development Officer, sold shares in a coordinated cluster totaling $708K over a 7-day window. The sales represent a modest 0.0085% of the company's $8.3B market cap and appear tied to option exercises, with no open-market buying observed.

Key Financial Metrics

Direction
selling
Total Value
$708.0K
Insiders
3

Key Facts

  • CFO Alexandra Balcom sold $370K in shares, following derivative exercises of over 22K shares (mostly non-cash).
  • Chief Development Officer Darlene Noci sold $247K in shares, concurrent with exercising 11K options.
  • Chief Legal Officer Deborah Miller sold $92K in shares, completing the cluster.
  • Total open-market sales: $708K across 3 C-suite insiders; no open-market purchases detected.
  • All transactions occurred between March 26 and April 1, 2026.

Financial Impact

$708,000 in insider sales over 7 days (0.0085% of $8.3B market cap)

insider ownershipmarket sentiment

Risk Factors

  • Perception of insider pessimism if sales continue in next quarter.
  • Concentration of selling among C-suite executives, though not material in dollar size.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1775248264993
18 reports for NUVL
Performance horizon
38% Hit rate 3 of 8 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 3, 2026